4 Healthcare Stock Stories For Tuesday Investment Wellness
GlaxoSmithKline plc (NYSE:GSK): Closing price $50.42
On Tuesday, GlaxoSmithKline and Theravance, Inc. announced that the Pulmonary-Allergy Drugs Advisory Committee to the FDA voted 11 Yes to 2 No, that the efficacy and safety data provide substantial evidence in support of approval of umeclidinium/vilanterol (UMEC/VI, 62.5/25mcg dose) for the long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients suffering from chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT): Closing price $1.45
The developer of oxygen-carrying therapeutics reported Tuesday that it has been issued patent#8,513,309 by the United States Patent and Trademark Office, titled Perfluorocarbons for use in Treating Pruritus. This patent covers methods for treating pruritus, a sensation that a patient instinctually tries to relieve by rubbing or scratching. The newly issued patent addresses part of the global dermatological drugs market, which is forecast to reach $24.4 billion by 2015, said the market research firm Visiongain. Oxygen Biotherapeutics is presently exploring commercialization strategies, which might include out-licensing, for prescription dermatologic indications of PFC-based products for conditions such as allergic contact dermatitis, psoriasis and acne.
Galectin Therapeutics Inc. (NASDAQ:GALT): Closing price $8.57
Galectin said Tuesday that it has received a notice of issuance from the U.S. Patent and Trademark Office for Patent Application Number 13/573,454, titled Galacto-rhamnogalacturonate compositions for the treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. The patent covers the firm’s carbohydrate-based galectin inhibitor compound GR-MD-02 for use in patients suffering with fatty liver disease with or without fibrosis or cirrhosis. Fatty liver disease affects up to 15 million Americans, results in severe scarring of the liver (cirrhosis), and there are no presently approved pharmaceutical therapies. Galectin is a developer of therapeutics which aim galectin proteins to treat fibrosis and cancer.
Northwest Biotherapeutics Inc. (NASDAQ:NWBO): Closing price $3.34
Northwest Biotherapeutics reported Tuesday that it has been issued another key United States patent (#8,518,636), covering a next generation process for making lower cost human dendritic cells of both a higher quality and higher reliability. This next generation system has already been okayed by FDA for use in the manufacturing for NW Bio’s clinical trials. These systems are currently in use producing the vaccines which already have been injected into the tumors of DCVax-Direct patients. Northwest is a biotech firm developing DCVax personalized immune therapies for solid tumor cancers.